Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane; Single-pass type I membrane protein. |
Domain | - |
Function |
May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation. |
Biological Process |
GO:0001818 negative regulation of cytokine production GO:0002228 natural killer cell mediated immunity GO:0002237 response to molecule of bacterial origin GO:0002367 cytokine production involved in immune response GO:0002370 natural killer cell cytokine production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002532 production of molecular mediator involved in inflammatory response GO:0002534 cytokine production involved in inflammatory response GO:0002683 negative regulation of immune system process GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002701 negative regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002716 negative regulation of natural killer cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002719 negative regulation of cytokine production involved in immune response GO:0002727 regulation of natural killer cell cytokine production GO:0002728 negative regulation of natural killer cell cytokine production GO:0007160 cell-matrix adhesion GO:0031348 negative regulation of defense response GO:0031589 cell-substrate adhesion GO:0032496 response to lipopolysaccharide GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032689 negative regulation of interferon-gamma production GO:0045088 regulation of innate immune response GO:0045824 negative regulation of innate immune response GO:0050777 negative regulation of immune response |
Molecular Function | - |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CD96 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CD96 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CD96 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CD96 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CD96 in various data sets.
|
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD96. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD96. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD96. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD96. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CD96 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CD96 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CD96 |
Name | CD96 molecule |
Aliases | TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ...... |
Chromosomal Location | 3p13-q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CD96 collected from DrugBank database. |
There is no record. |